Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1996-05-06
2001-05-15
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S093200, C424S093100, C424S093480, C424S200100, C424S184100, C424S826000
Reexamination Certificate
active
06231871
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to modified microorganisms suitable for use as live in ovo vaccines for avian species. The live in ovo vaccines of the present invention are useful for inducing immunity before or immediately after hatching against a virulent form of the modified microorganism or a microorganism immunologically related to the modified microorganism or a virulent organism or virus carrying an antigenic determinant expressed by the modified microorganism in the live vaccine. The subject live in ovo vaccines are particularly efficacious in enhancing the survival rate of newly-hatched poultry birds.
BACKGROUND OF THE INVENTION
Infection of avian species by microorganisms, viruses, helminths, yeasts and protozoans can have serious environmental, ecological and commercial implications. Not only are the birds themselves at risk, but there is also the potential of the infecting agent to spread to other animals, including humans.
The poultry industry is particularly vulnerable to significant economic losses due to the susceptibility of stock birds, and in particular newly-hatched stock birds, to rapidly spreading infections. In poultry birds, infection by Salmonella species, generally referred to as salmonellosis, is the most common form of infection causing high mortality rates. Many species of Salmonella also cause infection in humans and other animals and, hence, control of salmonellosis in poultry birds is of particular importance. Two of the most common species of Salmonella isolated from poultry birds are
Salmonella typhimurium
and
Salmonella enteritidis.
Both organisms contribute significantly to the outbreaks of salmonellosis and, in fact,
S. enteritidis
phage type 4 emerged as a significant threat to public health in Britain during the mid 1980's.
Chemotherapy and chemoprophylaxis have been used as forms of protective measures to combat poultry diseases such as salmonellosis. However, such measures are not always successful, are quite expensive, may lead to the development of drug resistance amongst infecting agents and are not necessarily acceptable to public health authorities for birds destined for human or animal consumption. For these and other related reasons, alternative forms of protection for avian species have been the subject of intense scientific research.
One form of protection proposed is the development of vaccines against poultry diseases. Live attenuated Salmonella vaccines have been shown to protect chickens (Cooper et al.,
Microb. Pathog.,
9: 255-265, 1990; Hassan and Curtiss III,
Res. Microbiol.,
141: 839-850, 1990). Furthermore, Salmonella strains with a transposon inserted at or near aroA of the aromatic biosynthetic pathway have been shown to be attenuated, yet still capable of residing in tissue for sufficient time to stimulate an immune response (Stocker,
Vaccine,
6: 141-145, 1988; U.S. Pat. No. 4,735,801; U.S. Pat. No. 5,210,035). Cooper, et al.,
Vaccine
10: 247-254, 1992, made two strains of
S. enteritidis
phage type 4 with mutations in the aroA gene. These mutant strains were used as a live oral vaccine against oral and intravenous challenge. The results presented by Cooper et al., supra, showed that the
S. enteritidis
vaccines were protective in chickens following oral ingestion.
Notwithstanding the purported efficacy of the live oral vaccines comprising Salmonella species in protecting chickens, newly-hatched birds are particularly susceptible to Salmonella infection and a high mortality rate immediately post-hatching can have serious economic consequences. Furthermore, administering live oral vaccines is not always convenient and difficulties may result in ensuring adequate doses are received by the birds. Another option, therefore, is to inoculate the birds when in ovo.
European Patent Application No 0 291 173 proposed the administration of a non-replicating immunogen designed to induce immunity in embryos prior to hatching. The method was said to be especially useful for immunizing birds against avian coccidiosis using a sporulated
Eimeria tenella
oocyst extract. U.S. Pat. No. 4,458,630 also teaches that birds can be immunized against Marek's disease by injecting eggs, prior to hatching, with a replicating viral vaccine. However, in both cases, inoculation was intra-embryo, such as into the yolk sac or chorion allantoic fluid. If bacteria were to be inoculated in such a manner, the bacteria would “blow” the egg, causing it to go rotten and causing the embryo to die.
There is a need, therefore, to improve the technology relating to in ovo vaccines so that avian species can be protected against challenge by virulent organisms such as virulent strains of Salmonella. In accordance with the present invention, the inventors have discovered that microorganisms rendered attenuated or avirulent may be inoculated into defined tissues in ovo and that birds upon hatching are protected from challenge with a corresponding wild-type microorganism. The method of the present invention also enables the use of the modified microorganisms to carry antigenic epitopes in the form of immunogens for other avian pathogens to induce immunity against those pathogens. The present invention represents a major breakthrough in protecting newly-hatched birds and offers significant commercial advantages to poultry management.
SUMMARY OF THE INVENTION
Accordingly, one aspect of the present invention provides a live in ovo vaccine for avian species comprising an attenuated microorganism which:
(a) exhibits auxotrophy to one or more growth factors, such that it is incapable of growing on a minimal medium in the absence of said one or more growth factors;
(b) is capable of colonizing one or more tissues in an embryo prior to hatching; and
(c) is capable of inducing before or immediately after hatching an immune response in the embryo against a virulent form of said microorganism or an immunologically cross-reactive microorganism or a virulent organism or virus carrying an antigenic determinant expressed by said attenuated microorganism.
Another aspect of the present invention contemplates a live in ovo vaccine for poultry birds comprising an attenuated Salmonella which:
(a) exhibits auxotrophy for one or more growth factors such that it is incapable of growing on a minimal medium in the absence of said one or more growth factors;
(b) is capable of colonizing one or more tissues in an embryo prior to hatching; and
(c) is capable of inducing before or immediately after hatching an immune response in the embryo against a virulent form of said Salmonella or an immunologically cross-reactive Salmonella or a virulent organism or virus carrying an antigenic determinant expressed by said avirulent Salmonella.
Yet another aspect of the present invention is directed to a method for immunizing an avian species against infection by a pathogenic microorganism said method comprising administering in ovo an attenuated microorganism which:
(a) exhibits auxotrophy to one or more growth factors such that it is incapable of growing on a minimal medium in the absence of said one or more growth factors; and
(b) is capable of colonizing one or more tissues in an embryo prior to hatching in an amount and under conditions effective to induce an immune response in the embryo before or immediately after hatching against a virulent form of said attenuated microorganism or an immunologically cross-reactive microorganism or virulent organism or virus carrying an antigenic determinant expressed by said attenuated microorganism.
Still yet another aspect of the present invention relates to a method for immunizing poultry birds against infection by a pathogenic microorganism said method comprising in ovo administration of a vaccine comprising an attenuated Salmonella which:
(a) exhibits auxotrophy to one or more growth factors such that it is incapable of growing on a minimal medium in the absence of said one or more growth factors; and
(b) is capable of colonizing one or more tissues in an embryo prior to hatching in an amount and under
American Cyanamid Company
Minnifield Nita
Renda Barbara L.
Rosenblum Anne M.
LandOfFree
Live in ovo vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live in ovo vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live in ovo vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2557873